Insmed Incorporated (INSM) fair value analysis
Nasdaq · Updated 2026-10-19
INSM price how computed
Valuation status
Awaiting full valuationINSM's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once INSM's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $96.27
- Sector
- Healthcare
- 12-month range
- $91.88–$211.41
- Market cap
- $21B
- From 52-week high
- -54.5%
- Shares outstanding
- 218M
- Rank in Healthcare by quality score
- #135 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases, with a focus on respiratory and rare infectious diseases. The company operates in the United States and internationally, serving patients across multiple markets.
INSM currently ranks #135 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $21B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.14B
- Net margin
- -76.9%
- EPS (TTM)
- $-4.57
- Gross margin
- 84.2%
- Debt / equity
- 0.77
- Revenue growth (3-yr avg)
- 146.0%
- Shares outstanding
- 218M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 22 · oversold
- 50-day average
- $118.87
- 200-day average
- $129.10
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▲ beat (+24.6%)
2026-03 ▲ beat (+24.0%)
2025-12 ▼ miss (-31.6%)
2025-09 ▼ miss (-27.7%)
2025-06 ▼ miss (-30.8%)
2025-03 ▼ miss (-18.3%)
2024-12 ▼ miss (-7.3%)
2024-09 ▼ miss (-4.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 24 buy · 0 hold · 0 sell (24 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $197
- Target vs last price
- +104.6%
What our data shows for INSM
- Shares are trading in the lower third of their 12-month price range of $91.88–$211.41.
- The 14-day relative strength index sits at an oversold 22.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- INSM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent INSM news
TickrTrends' derived news-sentiment signal for INSM is currently leaning positive, computed from recent coverage.
- Insmed CFO Sara Bonstein to Resign; INSM Reaffirms 2026 Revenue Guidance (gurufocus.com, 2026-10-05)
- INSM Maintains Overweight Rating -- Price Target Lowered to $207 (gurufocus.com, 2026-09-30)
- Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? (insidermonkey.com, 2026-09-28)
What people are saying
Follow the INSM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — INSM's Relative Strength Index moved from the neutral zone into oversold territory this week, indicating that the stock has experienced selling pressure recently. The Healthcare sector company's overall valuation assessment remains pending as TickrTrends awaits complete valuation data.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — INSM's 50/200-day trend state has shifted from mixed to downtrend this week, indicating a change in its short-term momentum relative to its longer-term direction. The stock remains in the Healthcare sector with a valuation verdict that is currently awaiting full valuation. This trend shift represents a notable technical development for investors monitoring the company's price action.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INSM stock undervalued?
INSM's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is INSM's TickrTrends verdict?
INSM is currently marked 'Awaiting full valuation' - a verdict publishes automatically once INSM's own trailing P/E history validates under our standards.
How does INSM compare to other Healthcare stocks?
INSM ranks #135 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is INSM overbought or oversold?
INSM's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does INSM report earnings next?
INSM's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does INSM usually beat earnings estimates?
Over its last 8 reported quarters INSM beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INSM?
Of 24 analysts covering INSM, 24 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $197 (+104.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.